Sienna concedes failure in pivotal acne trial — will the laser-managed therapy work in hair reduction?
Sienna Biopharmaceuticals’ first foray into pivotal trials is a bust.
The Westlake Village, CA biotech reported that its lead therapy, SNA-001, flunked two separate trials designed to test its efficacy when managed by laser tech. Shares $SNNA are down 20% in pre-market trading.
Instead of separating the patients into drug and control arms, researchers adopted a split-face method in which each side of the patient’s face got treated with laser and either SNA-001 or vehicle. Both treatments reduced acne lesion count from baseline — the primary endpoint — to a similar extent, and the differences were not significant in either the 810 nm laser (p=0.663) or 1064 nm laser (p=0.411) trial, which recruited 78 and 89 subjects respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.